Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, Endpoints News, Fierce Biotech and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 137d ago.
Quick answers
Why is "Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Roche’s Lung Cancer Pill Outperforms Rival Drugs in Late Trial Bloomberg.com · 139d ago
- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study Endpoints News · 139d ago
- Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS Fierce Biotech · 139d ago
- Roche drug sets new standard for KRAS-driven lung cancer STAT · 139d ago
- Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study FirstWord PHARMA · 139d ago
- Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial WSJ · 139d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Lung scans save lives: Denver man's early screening underscores dire need for more testing
A Denver man's life-saving lung scan during Lung Cancer Awareness Month spotlights urgent calls for expanded early screening nationwide.
Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B
The US Food and Drug Administration and Health Canada have approved bepirovirsen, marketed as Hibsago, as the first functional cure for chronic hepatitis B.
Newly discovered pathway fuels production of cancer-driving proteins
Stanford researchers have identified a protein translation pathway involving the METTL13 enzyme that drives cancer growth and drug resistance.
PayPal Beats Earnings Estimates. Does It Now Have a Shorter Path to Recovery?
PayPal raises its annual profit forecast and highlights turnaround progress amid mixed third-quarter results.